Gatehouse Bio
Gatehouse Bio develops precision therapeutics by decoding small RNA isoforms and designing oligonucleotides that target disease-specific RNA signals. The company uses an AI-powered Code-Breaker platform to map the functional landscape of small RNAs, discover disease-associated isoforms, and digitally design biomarker-guided oligonucleotide therapeutics. Its approach combines computational biology, machine learning, and synthetic oligonucleotide design to generate candidates for heterogeneous indications such as fibrosis, inflammation, and neurodegeneration. Gatehouse Bio operates as a TechBio (B2B-focused) drug developer with academic and industry partnerships to advance programs into preclinical and clinical development. The platform is positioned to scale across multiple therapeutic areas by enabling targeted, isoform-specific RNA interventions.
Gatehouse Bio
Gatehouse Bio develops precision therapeutics by decoding small RNA isoforms and designing oligonucleotides that target disease-specific RNA signals. The company uses an AI-powered Code-Breaker platform to map the functional landscape of small RNAs, discover disease-associated isoforms, and digitally design biomarker-guided oligonucleotide therapeutics. Its approach combines computational biology, machine learning, and synthetic oligonucleotide design to generate candidates for heterogeneous indications such as fibrosis, inflammation, and neurodegeneration. Gatehouse Bio operates as a TechBio (B2B-focused) drug developer with academic and industry partnerships to advance programs into preclinical and clinical development. The platform is positioned to scale across multiple therapeutic areas by enabling targeted, isoform-specific RNA interventions.